Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Reyes Candau-Chacon"'
Autor:
Richard Pazdur, Ann T. Farrell, Qing Zhou, Ping Zhao, Pengfei Song, Deborah Schmiel, Tiffany K. Ricks, Nitin Mehrotra, Susan Kirshner, Robert C. Kane, Candace Gomez-Broughton, Brenda J. Gehrke, Haw-Jyh Chiu, Reyes Candau-Chacon, Carolyn L. Yancey, Albert Deisseroth, Chia-Wen Ko, Donna Przepiorka
Preferred Terms included in grouped terms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04eb5dd9d2864438c9fd3c493117694a
https://doi.org/10.1158/1078-0432.22457625.v1
https://doi.org/10.1158/1078-0432.22457625.v1
Autor:
Nitin Mehrotra, Ping Zhao, Tiffany K. Ricks, Candace Gomez-Broughton, Carolyn L. Yancey, Donna Przepiorka, Chia-Wen Ko, Pengfei Song, Robert C. Kane, Richard Pazdur, Deborah Schmiel, Albert Deisseroth, Qing Zhou, Brenda J. Gehrke, Ann T. Farrell, Susan L. Kirshner, Reyes Candau-Chacon, Haw-Jyh Chiu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(18)
On December 3, 2014, the FDA granted accelerated approval of blinatumomab (Blincyto; Amgen, Inc.) for treatment of Philadelphia chromosome–negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL). Blinatumomab is a re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0422e1e4aacff33cf972ba96a7696d8c
https://pubmed.ncbi.nlm.nih.gov/26374073
https://pubmed.ncbi.nlm.nih.gov/26374073
Autor:
Kathleen A. Clouse, Patricia Cortazar, Laleh Amiri-Kordestani, Qiang Casey Xu, Shenghui W. Tang, Reyes Candau-Chacon, Nitin Mehrotra, Wendy C. Weinberg, Robert Justice, Sarah J. Schrieber, Patricia Hughes, Todd R. Palmby, Linan Ha, Xiao Hong Chen, Rajeshwari Sridhara, Lijun Zhang, Gideon M. Blumenthal, W. David McGuinn, Richard Pazdur, Lisa Skarupa, Jian Wang, Bo Chi, Ali Al-Hakim, Sarah Pope Miksinski, Anne Marie Russell, Qi Liu, Amna Ibrahim, Pengfei Song
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 20(17)
On February 22, 2013, the FDA licensed ado-trastuzumab emtansine (Kadcyla; Genentech, Inc.) for use as a single agent for the treatment of patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) who pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfd7a04966c3216add108edb7d97df43
https://pubmed.ncbi.nlm.nih.gov/24879797
https://pubmed.ncbi.nlm.nih.gov/24879797